Shares of Medidata Solutions Inc (NASDAQ:MDSO) have been assigned an average rating of “Buy” from the thirteen ratings firms that are covering the firm. One research analyst has rated the stock with a sell rating, two have issued a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $59.78.

A number of equities analysts recently weighed in on MDSO shares. Needham & Company LLC raised their price objective on Medidata Solutions from $60.00 to $65.00 and gave the company a “buy” rating in a report on Friday, February 10th. SunTrust Banks, Inc. raised Medidata Solutions from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $60.00 to $70.00 in a research note on Friday, February 10th. Jefferies Group LLC lifted their price target on Medidata Solutions from $41.00 to $46.00 and gave the stock an “underperform” rating in a research note on Tuesday, November 22nd. Zacks Investment Research cut Medidata Solutions from a “buy” rating to a “hold” rating in a research note on Thursday, January 5th. Finally, Pacific Crest set a $65.00 price target on Medidata Solutions and gave the stock a “buy” rating in a research note on Sunday, December 4th.

Medidata Solutions (NASDAQ:MDSO) opened at 57.43 on Tuesday. The stock’s 50 day moving average price is $54.65 and its 200-day moving average price is $53.09. Medidata Solutions has a 12 month low of $35.01 and a 12 month high of $58.77. The firm has a market capitalization of $3.21 billion, a price-to-earnings ratio of 112.61 and a beta of 1.61.

Medidata Solutions (NASDAQ:MDSO) last announced its quarterly earnings data on Thursday, February 9th. The company reported $0.33 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.26 by $0.07. The company had revenue of $124.50 million for the quarter, compared to analysts’ expectations of $124.15 million. Medidata Solutions had a return on equity of 10.82% and a net margin of 6.25%. Medidata Solutions’s revenue for the quarter was up 25.9% compared to the same quarter last year. During the same period last year, the firm posted $0.27 EPS. Equities analysts anticipate that Medidata Solutions will post $1.24 EPS for the current fiscal year.

In other news, Vice Chairman Steven Isaac Hirschfeld sold 10,000 shares of Medidata Solutions stock in a transaction that occurred on Wednesday, December 21st. The stock was sold at an average price of $51.02, for a total value of $510,200.00. Following the sale, the insider now directly owns 40,400 shares in the company, valued at approximately $2,061,208. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO Tarek Sherif sold 7,500 shares of Medidata Solutions stock in a transaction that occurred on Thursday, March 2nd. The stock was sold at an average price of $57.06, for a total value of $427,950.00. Following the completion of the sale, the chief executive officer now owns 825,820 shares in the company, valued at $47,121,289.20. The disclosure for this sale can be found here. Insiders sold a total of 55,000 shares of company stock worth $2,927,525 over the last ninety days. Insiders own 6.70% of the company’s stock.

Several large investors have recently modified their holdings of MDSO. Arrowpoint Asset Management LLC increased its position in shares of Medidata Solutions by 21.1% in the fourth quarter. Arrowpoint Asset Management LLC now owns 799,877 shares of the company’s stock worth $39,730,000 after buying an additional 139,567 shares in the last quarter. FMR LLC increased its position in shares of Medidata Solutions by 12.3% in the fourth quarter. FMR LLC now owns 7,576,918 shares of the company’s stock worth $376,345,000 after buying an additional 830,073 shares in the last quarter. Arrowgrass Capital Partners US LP increased its position in shares of Medidata Solutions by 26.9% in the third quarter. Arrowgrass Capital Partners US LP now owns 116,315 shares of the company’s stock worth $6,486,000 after buying an additional 24,651 shares in the last quarter. Fred Alger Management Inc. increased its position in shares of Medidata Solutions by 60.8% in the fourth quarter. Fred Alger Management Inc. now owns 988,781 shares of the company’s stock worth $49,113,000 after buying an additional 373,763 shares in the last quarter. Finally, Profund Advisors LLC increased its position in shares of Medidata Solutions by 19.3% in the third quarter. Profund Advisors LLC now owns 9,575 shares of the company’s stock worth $534,000 after buying an additional 1,549 shares in the last quarter. Hedge funds and other institutional investors own 99.63% of the company’s stock.

Your IP Address:

About Medidata Solutions

Medidata Solutions Inc (Medidata) is a provider of cloud-based solutions for life sciences. The Company provides cloud-based solutions for clinical research in life sciences, offering platform technology that focuses on the clinical development. The Medidata Clinical Cloud provides a platform of technology and data analytics solutions designed to manage activities across clinical development.

5 Day Chart for NASDAQ:MDSO

Receive News & Stock Ratings for Medidata Solutions Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions Inc and related stocks with our FREE daily email newsletter.